Telix Pharmaceuticals
TLX
11.12
+0.34
+3.15%
Telix Pharmaceuticals
US · TLX
#2345 by market cap
Listed 2024
11.12
+0.34
+3.15%
Live - 5344 symbols - heartbeat 525s ago
· 2026-10-08 07:11
Pre-market
11.00
-1.08%
After-hours
11.12
0.00%
- Market cap
- 3.77B
- P/E (TTM)i
- 114.64
- P/Bi
- 9.07
- EPSi
- -0.02
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on TLX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.68, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +55.61% YoY
Margins
- Gross margin
- 53.05%
- Operating margin
- 2.25%
- Net margin
- -0.89%
Key ratios & quality
- Enterprise valuei
- 4.04B
- Altman Z-Scorei
- 3.68
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 108.91M | 332.98M | 516.55M | 803.79M |
| Gross profit | 137.46K | 659.47K | 2.04M | 1.70M | 64.58M | 209.53M | 336.16M | 426.44M |
| Selling & admin expenses | 6.39M | 8.11M | 14.77M | 29.58M | 59.47M | 89.38M | 152.19M | 237.15M |
| Research & development | 13.17M | 14.82M | 17.75M | 24.74M | 54.89M | 85.32M | 127.93M | 171.25M |
| Operating profit | -19.47M | -28.18M | -38.28M | -71.62M | -50.48M | 34.97M | 55.58M | 18.05M |
| Pretax profit | -11.07M | -21.79M | -36.86M | -58.33M | -67.09M | 2.59M | 37.92M | -5.27M |
| Tax | -1.33M | -2.28M | -2.34M | 32.62K | 3.71M | -1.61M | 4.23M | 1.86M |
| Net profit | -9.74M | -19.51M | -34.51M | -58.36M | -70.80M | 4.21M | 33.69M | -7.13M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.05 | -0.08 | -0.13 | -0.21 | -0.23 | 0.01 | 0.10 | -0.02 |
| Line item | 2023-09 | 2023-12 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | -- | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | -- | -- | -- | -- | -- | -- |
| Pretax profit | -- | -- | -- | -- | -- | -- |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -- | -- | -- | -- | -- | -- |
| Basic EPS | -- | -- | -- | -- | -- | -- |
| Diluted EPS | -- | -- | -- | -- | -- | -- |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 25.26M | 41.08M | 71.99M | 34.46M | 117.85M | 158.69M | 570.12M | 330.28M |
| Cash & ST investments | 18.15M | 31.22M | 59.93M | 15.97M | 79.14M | 84.30M | 440.00M | 141.87M |
| Inventory | 452.59K | 379.44K | 486.69K | 2.50M | 5.77M | 12.74M | 23.62M | 37.08M |
| Total assets | 54.03M | 71.83M | 121.34M | 79.60M | 173.72M | 277.26M | 940.38M | 1.16B |
| Total current liabilities | 5.81M | 7.44M | 15.34M | 27.53M | 58.20M | 111.37M | 205.09M | 231.62M |
| Short-term debt | 798.04K | 343.04K | 589.71K | 458.14K | 436.07K | 1.07M | 13.31M | 18.66M |
| Long-term debt | 420.03K | 204.42K | 73.04K | -- | 2.25M | 5.95M | 341.81M | 391.91M |
| Total liabilities | 16,767,264.47 | 22,771,473.18 | 60,589,867.99 | 78,040,276.05 | 119,287,862.09 | 174,613,000.00 | 587,442,000.00 | 748,610,000.00 |
| Total equity | 37.27M | 49.06M | 60.75M | 1.56M | 54.43M | 102.65M | 352.94M | 415.38M |
| Retained earnings | -14.23M | -33.66M | -71.47M | -125.75M | -185.60M | -187.12M | -152.91M | -154.54M |
| Line item | 2023-09 | 2023-12 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | -- | 158.69M | 570.12M | 398.01M | 330.28M | 488.02M |
| Cash & ST investments | -- | 84.30M | 440.00M | 207.16M | 141.87M | 251.91M |
| Inventory | -- | 12.74M | 23.62M | 35.23M | 37.08M | 39.03M |
| Total assets | -- | 277.26M | 940.38M | 1.19B | 1.16B | 1.36B |
| Total current liabilities | -- | 111.37M | 205.09M | 298.58M | 231.62M | 242.34M |
| Short-term debt | -- | 1.07M | 13.31M | 21.06M | 18.66M | 15.42M |
| Long-term debt | -- | 5.95M | 341.81M | 371.48M | 391.91M | 504.88M |
| Total liabilities | -- | 174,613,000.00 | 587,442,000.00 | 768,011,000.00 | 748,610,000.00 | 874,176,000.00 |
| Total equity | -- | 102.65M | 352.94M | 421.94M | 415.38M | 487.68M |
| Retained earnings | -- | -187.12M | -152.91M | -150.98M | -154.54M | -110.90M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -- | -- | -- | -- | -- | -- | -- | -- |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- | -- | -- |
| Free cash flow | -14.62M | -16.66M | 1.26M | -43.98M | -52.95M | 7.16M | 5.31M | -61.07M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 31.68M | 27.03M | 2.74M | 123.16M | 4.17M | 662.00K | 1.81M |
| Ending cash balance | 18.15M | 31.22M | 59.93M | 15.97M | 79.14M | 84.30M | 440.00M | 141.87M |
| Line item | 2023-09 | 2023-12 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -- | -- | -- | -- | -- | -- |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | 13.73M | -15.08M | -- | -- | -- | -- |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 2.27M | 5.60K | -- | -- | -- | -- |
| Ending cash balance | 88.32M | 84.30M | -- | -- | -- | -- |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -25.73 | -45.20 | -62.85 | -187.31 | -252.91 | 4.56 | 13.65 | -1.85 |
| ROA %i | -20.75 | -31.00 | -35.73 | -58.09 | -55.90 | 1.60 | 5.11 | -0.68 |
| ROIC %i | -25.59 | -40.57 | -59.67 | -169.21 | -208.25 | 11.02 | 10.92 | 2.14 |
| 5-year avg ROE %i | -- | -- | -- | -66.81 | -114.80 | -108.58 | -96.59 | -84.39 |
| EBIT margin %i | -8,037.67 | -823.93 | -999.15 | -1,536.28 | -58.93 | 3.39 | 11.82 | 4.37 |
| FCF / sales %i | -- | -- | 35.00 | -- | -- | 2.64 | 1.15 | -- |
| Current ratioi | 4.35 | 5.52 | 4.69 | 1.25 | 2.02 | 1.42 | 2.78 | 1.43 |
| Quick ratioi | 4.15 | 5.33 | 4.53 | 1.09 | 1.82 | 1.20 | 2.63 | 1.21 |
| Debt / assetsi | 2.25 | 2.08 | 1.40 | 2.31 | 4.09 | 4.42 | 38.30 | 40.13 |
| LT debt / equityi | 1.13 | 2.34 | 1.82 | 88.37 | 12.26 | 10.91 | 98.28 | 107.96 |
| Interest coveragei | -540.52 | -11.92 | -39.80 | -14.42 | -13.74 | 1.22 | 2.54 | 0.87 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 195.60 | 254.74 | 352.32 | 425.94 | 94.69 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | 78.51 | -- | -- |
| Line item | 2023-09 | 2023-12 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | 4.56 | 13.65 | 2.65 | -1.85 | 7.37 |
| ROA %i | -- | 1.60 | 5.11 | 1.08 | -0.68 | 2.63 |
| ROIC %i | -- | 11.02 | 10.92 | 4.74 | 2.14 | 6.39 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | 3.39 | 11.82 | 6.53 | 4.37 | 8.15 |
| FCF / sales %i | -- | 2.64 | 1.15 | -- | -- | -- |
| Current ratioi | -- | 1.42 | 2.78 | 1.33 | 1.43 | 2.01 |
| Quick ratioi | -- | 1.20 | 2.63 | 1.13 | 1.21 | 1.74 |
| Debt / assetsi | -- | 4.42 | 38.30 | 35.15 | 40.13 | 42.58 |
| LT debt / equityi | -- | 10.91 | 98.28 | 94.13 | 107.96 | 115.74 |
| Interest coveragei | -- | 1.22 | 2.54 | 1.21 | 0.87 | 1.66 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Precision Medicine is the largest reported line at 77.37% of revenue, across 4 reported segments.
- The next-largest line, Manufacturing Solutions, is a distant second at 30.49% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Precision Medicine77.37%
Manufacturing Solutions30.49%
Therapeutics1.15%
Region
United States97.65%
China1.22%
Other countries1.13%
Quote time 2026-10-08 07:11:57 · For reference only, not investment advice and not tailored to your situation.